424 related articles for article (PubMed ID: 28388953)
41. Efficacy of parenteral vaccination against porcine circovirus type 2 (PCV2) in seropositive piglets.
Gamage LN; McIntosh KA; Parker S; Harding J; Krakowka S; Ellis J
Can J Vet Res; 2012 Oct; 76(4):301-7. PubMed ID: 23543956
[TBL] [Abstract][Full Text] [Related]
42. A field efficacy trial of a trivalent vaccine containing porcine circovirus type 2a and 2b, and Mycoplasma hyopneumoniae in three herds.
Um H; Yang S; Oh T; Cho H; Park KH; Suh J; Chae C
Vet Med Sci; 2022 Mar; 8(2):578-590. PubMed ID: 34687172
[TBL] [Abstract][Full Text] [Related]
43. Vaccination of piglets at 1 week of age with an inactivated Mycoplasma hyopneumoniae vaccine reduces lung lesions and improves average daily gain in body weight.
Wilson S; Van Brussel L; Saunders G; Taylor L; Zimmermann L; Heinritzi K; Ritzmann M; Banholzer E; Eddicks M
Vaccine; 2012 Dec; 30(52):7625-9. PubMed ID: 23084853
[TBL] [Abstract][Full Text] [Related]
44. Effect of Maternal Antibody Transfer on Antibody Dynamics and Control of Porcine Circovirus Type 2 Infection in Offspring.
Dvorak CMT; Payne BJ; Seate JL; Murtaugh MP
Viral Immunol; 2018; 31(1):40-46. PubMed ID: 28817375
[TBL] [Abstract][Full Text] [Related]
45. Divergent clinical outcomes depending on the sequential infection order of porcine circovirus type 2 and Mycoplasma hyopneumoniae.
Suh J; Ham S; Chae C
Vet Microbiol; 2024 May; 292():110060. PubMed ID: 38520754
[TBL] [Abstract][Full Text] [Related]
46. Concurrent vaccinations against PCV2 and PRRSV: study on the specific immunity and clinical protection in naturally infected pigs.
Martelli P; Ardigò P; Ferrari L; Morganti M; De Angelis E; Bonilauri P; Luppi A; Guazzetti S; Caleffi A; Borghetti P
Vet Microbiol; 2013 Mar; 162(2-4):558-571. PubMed ID: 23206413
[TBL] [Abstract][Full Text] [Related]
47. Comparison of cytokine profiles in peripheral blood mononuclear cells between piglets born from Porcine circovirus 2 vaccinated and non-vaccinated sows.
Oliver-Ferrando S; Segalés J; Sibila M; Díaz I
Vet Microbiol; 2018 Feb; 214():148-153. PubMed ID: 29408027
[TBL] [Abstract][Full Text] [Related]
48. Occurrence and severity of lung lesions in slaughter pigs vaccinated against Mycoplasma hyopneumoniae with different strategies.
Hillen S; von Berg S; Köhler K; Reinacher M; Willems H; Reiner G
Prev Vet Med; 2014 Mar; 113(4):580-8. PubMed ID: 24485705
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of cell-mediated immune responses against porcine circovirus type 2 (PCV2) Cap and Rep proteins after vaccination with a commercial PCV2 sub-unit vaccine.
Fort M; Sibila M; Nofrarías M; Pérez-Martín E; Olvera A; Mateu E; Segalés J
Vet Immunol Immunopathol; 2012 Nov; 150(1-2):128-32. PubMed ID: 23010221
[TBL] [Abstract][Full Text] [Related]
50. Protective immunity induced by concurrent intradermal injection of porcine circovirus type 2 and Mycoplasma hyopneumoniae inactivated vaccines in pigs.
Lee SI; Jeong CG; Ul Salam Mattoo S; Nazki S; Prasad Aganja R; Kim SC; Khatun A; Oh Y; Noh SH; Lee SM; Kim WI
Vaccine; 2021 Oct; 39(45):6691-6699. PubMed ID: 34538524
[TBL] [Abstract][Full Text] [Related]
51. Porcine circovirus type 2 infection decreases the efficacy of a modified live porcine reproductive and respiratory syndrome virus vaccine.
Opriessnig T; McKeown NE; Harmon KL; Meng XJ; Halbur PG
Clin Vaccine Immunol; 2006 Aug; 13(8):923-9. PubMed ID: 16893993
[TBL] [Abstract][Full Text] [Related]
52. Virological and serological characterization of vaccinated and non-vaccinated piglet subpopulations coming from vaccinated and non-vaccinated sows.
Fraile L; Segalés J; Ticó G; López-Soria S; Valero O; Nofrarías M; Huerta E; Llorens A; López-Jiménez R; Pérez D; Sibila M
Prev Vet Med; 2015 May; 119(3-4):153-61. PubMed ID: 25748003
[TBL] [Abstract][Full Text] [Related]
53. A field efficacy and safety trial in the Netherlands in pigs vaccinated at 3 weeks of age with a ready-to-use porcine circovirus type 2 and
Kaalberg L; Geurts V; Jolie R
Porcine Health Manag; 2017; 3():23. PubMed ID: 29152324
[TBL] [Abstract][Full Text] [Related]
54. Effect of vaccination with selective bacterins on conventional pigs infected with type 2 porcine circovirus.
Opriessnig T; Yu S; Gallup JM; Evans RB; Fenaux M; Pallares F; Thacker EL; Brockus CW; Ackermann MR; Thomas P; Meng XJ; Halbur PG
Vet Pathol; 2003 Sep; 40(5):521-9. PubMed ID: 12949409
[TBL] [Abstract][Full Text] [Related]
55. Field evaluation of piglet vaccination with a
Duivon D; Corrégé I; Hémonic A; Rigaut M; Roudaut D; Jolie R
Porcine Health Manag; 2018; 4():4. PubMed ID: 29375890
[TBL] [Abstract][Full Text] [Related]
56. Comparison of the effectiveness of passive (dam) versus active (piglet) immunization against porcine circovirus type 2 (PCV2) and impact of passively derived PCV2 vaccine-induced immunity on vaccination.
Opriessnig T; Patterson AR; Madson DM; Pal N; Ramamoorthy S; Meng XJ; Halbur PG
Vet Microbiol; 2010 May; 142(3-4):177-83. PubMed ID: 19913369
[TBL] [Abstract][Full Text] [Related]
57. A PCV2 vaccine based on genotype 2b is more effective than a 2a-based vaccine to protect against PCV2b or combined PCV2a/2b viremia in pigs with concurrent PCV2, PRRSV and PPV infection.
Opriessnig T; O'Neill K; Gerber PF; de Castro AM; Gimenéz-Lirola LG; Beach NM; Zhou L; Meng XJ; Wang C; Halbur PG
Vaccine; 2013 Jan; 31(3):487-94. PubMed ID: 23174198
[TBL] [Abstract][Full Text] [Related]
58. Plasmid-mediated growth hormone-releasing hormone efficacy in reducing disease associated with Mycoplasma hyopneumoniae and porcine reproductive and respiratory syndrome virus infection.
Thacker EL; Holtkamp DJ; Khan AS; Brown PA; Draghia-Akli R
J Anim Sci; 2006 Mar; 84(3):733-42. PubMed ID: 16478966
[TBL] [Abstract][Full Text] [Related]
59. A chimeric porcine circovirus (PCV) with the immunogenic capsid gene of the pathogenic PCV type 2 (PCV2) cloned into the genomic backbone of the nonpathogenic PCV1 induces protective immunity against PCV2 infection in pigs.
Fenaux M; Opriessnig T; Halbur PG; Elvinger F; Meng XJ
J Virol; 2004 Jun; 78(12):6297-303. PubMed ID: 15163723
[TBL] [Abstract][Full Text] [Related]
60. A commercial porcine circovirus (PCV) type 2a-based vaccine reduces PCV2d viremia and shedding and prevents PCV2d transmission to naïve pigs under experimental conditions.
Opriessnig T; Xiao CT; Halbur PG; Gerber PF; Matzinger SR; Meng XJ
Vaccine; 2017 Jan; 35(2):248-254. PubMed ID: 27919634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
